Ghent University Academic Bibliography

Advanced

Patterns of transmitted HIV drug resistance in Europe vary by risk group

Dineke Frentz, David van de Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, Daniel Struck, Jean-Claude Schmit, Jurgen Vercauteren, et al. (2014) PLOS ONE. 9(4).
abstract
Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
INFECTION, MUTATIONS, USERS, PREVALENCE, EPIDEMIOLOGY, INDIVIDUALS, TRANSMISSION, ACTIVE ANTIRETROVIRAL THERAPY, APPEARANCE, POPULATIONS
journal title
PLOS ONE
PLoS One
volume
9
issue
4
article number
e94495
pages
7 pages
Web of Science type
Article
Web of Science id
000336909100083
JCR category
MULTIDISCIPLINARY SCIENCES
JCR impact factor
3.234 (2014)
JCR rank
9/57 (2014)
JCR quartile
1 (2014)
ISSN
1932-6203
DOI
10.1371/journal.pone.0094495
language
English
UGent publication?
yes
classification
A1
copyright statement
I have retained and own the full copyright for this publication
id
5913127
handle
http://hdl.handle.net/1854/LU-5913127
date created
2015-03-26 09:15:23
date last changed
2016-12-21 15:41:23
@article{5913127,
  abstract     = {Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. 
Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. 
Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48\%), followed by heterosexuals (1501, 35\%) and injection drug users (IDU) (355, 8\%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected ({\textlangle}1 year) (p{\textlangle}0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1\%), followed by heterosexuals (6.6\%) and IDU (5.1\%, p{\textlangle}0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6\% in MSM, 3.3\% in heterosexuals and 2.0\% in IDU (p = 0.001). A significant increase in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). 
Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.},
  articleno    = {e94495},
  author       = {Frentz, Dineke and van de Vijver, David and Abecasis, Ana and Albert, Jan and Hamouda, Osamah and J{\o}rgensen, Louise and K{\"u}cherer, Claudia and Struck, Daniel and Schmit, Jean-Claude and Vercauteren, Jurgen and {\AA}sj{\"o}, Birgitta and Balotta, Claudia and Bergin, Colm and Beshkov, Danail and Camacho, Ricardo and Clotet, Bonaventura and Griskevicius, Algirdas and Grossman, Zehava and Horban, Andrzej and Kolupajeva, Tatjana and Korn, Klaus and Kostrikis, Leondios and Linka, Kirsi Liitsola Marek and Nielsen, Claus and Otelea, Dan and Paraskevis, Dimitrios and Paredes, Roger and Poljak, Mario and Puchhammer-St{\"o}ckl, Elisabeth and S{\"o}nnerborg, Anders and Stanekova, Danica and Stanojevic, Maja and Vandamme, Anne-Mieke and Boucher, Charles and Wensing, Annemarie and SPREAD Programme, on behalf of the and Vandekerckhove, Linos},
  issn         = {1932-6203},
  journal      = {PLOS ONE},
  keyword      = {INFECTION,MUTATIONS,USERS,PREVALENCE,EPIDEMIOLOGY,INDIVIDUALS,TRANSMISSION,ACTIVE ANTIRETROVIRAL THERAPY,APPEARANCE,POPULATIONS},
  language     = {eng},
  number       = {4},
  pages        = {7},
  title        = {Patterns of transmitted HIV drug resistance in Europe vary by risk group},
  url          = {http://dx.doi.org/10.1371/journal.pone.0094495},
  volume       = {9},
  year         = {2014},
}

Chicago
Frentz, Dineke, David van de Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, et al. 2014. “Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group.” Plos One 9 (4).
APA
Frentz, D., van de Vijver, D., Abecasis, A., Albert, J., Hamouda, O., Jørgensen, L., Kücherer, C., et al. (2014). Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLOS ONE, 9(4).
Vancouver
1.
Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLOS ONE. 2014;9(4).
MLA
Frentz, Dineke, David van de Vijver, Ana Abecasis, et al. “Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group.” PLOS ONE 9.4 (2014): n. pag. Print.